• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H2 2012 Product Image

Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H2 2012

  • ID: 2298657
  • December 2012
  • 101 pages
  • Global Markets Direct

Streptococcus Pneumoniae (Pneumococcus) Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections. Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Streptococcus Pneumoniae (Pneumococcus) Infections Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections 10
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Development by Companies 12
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Products under Development by Companies 20
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics Development 23
GlaxoSmithKline plc 23
Daiichi Sankyo Company, Ltd 24
Merck & Co., Inc. 25
Dainippon Sumitomo Pharma Co., Ltd. 26
ACE BioSciences A/S 27
Intercell AG 28
SIGA Technologies, Inc. 29
Panacea Biotec Limited 30
Eurocine Vaccines AB 31
China National Biotec Group 32
Mucosis B.V. 33
GlycoVaxyn AG 34
Aquapharm Biodiscovery Limited 35
aRigen Pharmaceuticals, Inc. 36
Nabriva Therapeutics AG 37
Sinovac Biotech Ltd. 38
Genocea Biosciences, Inc. 39
NasVax Ltd. 40
Morphochem AG 41
Streptococcus Pneumoniae (Pneumococcus) Infections – Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
Pneumococcal Conjugate Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Sortase Inhibitor - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BC-3781 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Pneumococcus Antibodies - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ACE-720 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
V-114 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Pneumococcal Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PneuGEM Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CPG 7909 + Pneumococcal Vaccines - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Heptavalent Pneumococcal Conjugate Vaccine + Polyvalent Pneumococcal Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GSK-2202083A + Prevenar 13 + Rotarix - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2189242-A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
JNJ-Q2 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Streptococcus Pneumoniae Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Nasal Pneumococcal Vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Prevenar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Prevenar - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
S. Pneumoniae Paediatric Next Generation Vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Inactivated Influenza Vaccine + 23-Valent Pneumococcal Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Synflorix + Infanrix Hexa - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
GEN-004 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Pneumococcal Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GSK2189242A + GSK1024850A - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
V-419 + Prevnar 13 + RotaTeq - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 79
Pneumococcal Polysaccharides Vaccine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
AQP-182 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Compound G-1 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
MCB-3837 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SM-295291 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SM-369926 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Drug Profile Updates 86
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Discontinued Products 90
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Dormant Products 91
Streptococcus Pneumoniae (Pneumococcus) Infections – Product Development Milestones 93
Featured News & Press Releases 93
Nov 16, 2012: GlaxoSmithKline Announces Publication Of Positive Results Of Synflorix European Clinical Trial In Lancet In Preventing Invasive Pneumococcal Disease 93
Oct 17, 2012: Durata Therapeutics Announces Preclinical Data Supporting Clinical Development Of Dalbavancin For Treatment Of Pneumonia 94
Oct 09, 2012: GAVI Alliance To Introduce Synflorix Pneumococcal Vaccine In Pakistan 94
Sep 17, 2012: GSK Announces Submission For New Indication For Synflorix In Europe 95
Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 96
Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 97
Aug 06, 2012: Aquapharm Biodiscovery Discovers New Antibiotic Compound 97
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 98
Apr 26, 2011: National Advisory Committee On Immunization Recommends On Use Of Prevnar 13 99
Mar 03, 2011: Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 101

List of Tables
Number of Products Under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H2 2012 10
Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Development by Companies, H2 2012 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2012 22
GlaxoSmithKline plc, H2 2012 23
Daiichi Sankyo Company, Ltd, H2 2012 24
Merck & Co., Inc., H2 2012 25
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 26
ACE BioSciences A/S, H2 2012 27
Intercell AG, H2 2012 28
SIGA Technologies, Inc., H2 2012 29
Panacea Biotec Limited, H2 2012 30
Eurocine Vaccines AB, H2 2012 31
China National Biotec Group, H2 2012 32
Mucosis B.V., H2 2012 33
GlycoVaxyn AG, H2 2012 34
Aquapharm Biodiscovery Limited, H2 2012 35
aRigen Pharmaceuticals, Inc., H2 2012 36
Nabriva Therapeutics AG, H2 2012 37
Sinovac Biotech Ltd., H2 2012 38
Genocea Biosciences, Inc., H2 2012 39
NasVax Ltd., H2 2012 40
Morphochem AG, H2 2012 41
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 47
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Drug Profile Updates 86
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Discontinued Products 90
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Dormant Products 91
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Dormant Products (Contd..1) 92

List of Figures
Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H2 2012 10
Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Route of Administration, H2 2012 44
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Molecule Type, H2 2012 46
Assessment by Stage and Molecule Type, H2 2012 47

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos